PI3K/mTOR Inhibitor-4
Modify Date: 2024-04-05 15:03:23
PI3K/mTOR Inhibitor-4 structure
|
Common Name | PI3K/mTOR Inhibitor-4 | ||
|---|---|---|---|---|
| CAS Number | 2361215-32-7 | Molecular Weight | 535.54 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C27H22FN3O6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PI3K/mTOR Inhibitor-4PI3K/mTOR Inhibitor-4 is an orally active pan-class I PI3K/mTOR inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC50 values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer[1]. |
| Name | PI3K/mTOR Inhibitor-4 |
|---|
| Description | PI3K/mTOR Inhibitor-4 is an orally active pan-class I PI3K/mTOR inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC50 values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
PI3Kα:0.63 nM (IC50) PI3Kδ:9.2 nM (IC50) mTOR:13.85 nM (IC50) PI3Kβ:94.54 nM (IC50) PI3Kγ:22 nM (IC50) |
| In Vitro | PI3K/mTOR Inhibitor-4 (compound 8d-1) has enzymatic inhibition activity for PI3Kα, PI3Kδ, mTOR, PI3Kβ and PI3Kγ with IC50 values of 0.63 nM, 9.2 nM, 13.85 nM, 94.54 nM and 22 nM, respectively[1]. PI3K/mTOR Inhibitor-4 shows potent anti-proliferation activity in A549, Hela, HCT-116, HepG2, A375 and MCF-7 cells with IC50 values of 1.35 nM, 1.22 nM, 13.44 nM, 1.08 nM, 18.4 nM and 8.26 nM, respectively[1]. PI3K/mTOR Inhibitor-4 (2.5-10 µM; 24 h) inhibits the PI3K/AKT/mTOR pathway[1]. Cell Viability Assay[1] Cell Line: PC12 and LO2 cells Concentration: 0.625-20 µM Incubation Time: 72 h Result: Showed low toxicity in concentrations from 0.625 µM to 20 µM. Western Blot Analysis[1] Cell Line: Hela cells Concentration: 2.5, 5 and 10 µM Incubation Time: 24 h Result: Dose-dependently decreased the level of phosphorylation of AKT and its downstream target S6 in Hela cell line. |
| In Vivo | PI3K/mTOR Inhibitor-4 (compound 8d-1) (i.v., oral; 1mg/kg, 10 mg/kg) displays favorable pharmacokinetic parameters in Sprague−Dawley rats[1]. PI3K/mTOR Inhibitor-4 (oral; 10-50 mg/kg) shows significant efficiency in Hela/A549 tumor xenograft models without causing significant weight loss and toxicity[1]. Animal Model: SD rats (male; 200-220 g)[1] Dosage: 1, 10 mg/kg Administration: Intravenous, oral Result: IV (1 mg/kg) PO (10 mg/kg) CL (ml/min/kg) Vss (ml/kg) Tmax (h) Cmax (ng/ml) AUCinf (ng*h/ml) t1/2 (h) F(%) 8.6 1199.81 2.67 886.67 4753.35 1.78 24.1 Animal Model: BALB/c nude mice (female; 6-7 weeks; 18-22 g)[1] Dosage: 10, 20, 40, 50 mg/kg/d (Hela model) and 20, 40 mg/kg/d (A549 model) Administration: Oral Result: Inhibited the growth of xenograft tumors in a dose-dependent manner. |
| Molecular Formula | C27H22FN3O6S |
|---|---|
| Molecular Weight | 535.54 |